BRPI9609033B8 - composição e emulsão para a liberação controlada de uma substância. - Google Patents

composição e emulsão para a liberação controlada de uma substância.

Info

Publication number
BRPI9609033B8
BRPI9609033B8 BRPI9609033A BR9609033A BRPI9609033B8 BR PI9609033 B8 BRPI9609033 B8 BR PI9609033B8 BR PI9609033 A BRPI9609033 A BR PI9609033A BR 9609033 A BR9609033 A BR 9609033A BR PI9609033 B8 BRPI9609033 B8 BR PI9609033B8
Authority
BR
Brazil
Prior art keywords
substance
composition
controlled release
emulsion
hvlcm
Prior art date
Application number
BRPI9609033A
Other languages
English (en)
Other versions
BR9609033A (pt
BR9609033B1 (pt
Inventor
J Tipton Arthur
J Holl Richard
Original Assignee
Durect Corp
Southern Biosystems
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27044421&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI9609033(B8) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from US08/474,337 external-priority patent/US5747058A/en
Application filed by Durect Corp, Southern Biosystems filed Critical Durect Corp
Publication of BR9609033A publication Critical patent/BR9609033A/pt
Publication of BR9609033B1 publication Critical patent/BR9609033B1/pt
Publication of BRPI9609033B8 publication Critical patent/BRPI9609033B8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/60—Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
    • A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
    • A61L15/20—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons containing organic materials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
    • A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
    • A61L15/42—Use of materials characterised by their function or physical properties
    • A61L15/44—Medicaments
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L24/00—Surgical adhesives or cements; Adhesives for colostomy devices
    • A61L24/001—Use of materials characterised by their function or physical properties
    • A61L24/0015—Medicaments; Biocides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L26/00—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
    • A61L26/0061—Use of materials characterised by their function or physical properties
    • A61L26/0066—Medicaments; Biocides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
    • A61L27/54—Biologically active materials, e.g. therapeutic substances
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
    • A61L31/14—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
    • A61L31/16—Biologically active materials, e.g. therapeutic substances
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q11/00—Preparations for care of the teeth, of the oral cavity or of dentures; Dentifrices, e.g. toothpastes; Mouth rinses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/20—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials
    • A61L2300/23—Carbohydrates
    • A61L2300/236—Glycosaminoglycans, e.g. heparin, hyaluronic acid, chondroitin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
    • A61L2300/42—Anti-thrombotic agents, anticoagulants, anti-platelet agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/60—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a special physical form
    • A61L2300/602—Type of release, e.g. controlled, sustained, slow
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/60—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a special physical form
    • A61L2300/62—Encapsulated active agents, e.g. emulsified droplets
    • A61L2300/622—Microcapsules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/80—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a special chemical form
    • A61L2300/802—Additives, excipients, e.g. cyclodextrins, fatty acids, surfactants

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Materials Engineering (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Surgery (AREA)
  • Diabetes (AREA)
  • Oral & Maxillofacial Surgery (AREA)
  • Communicable Diseases (AREA)
  • Vascular Medicine (AREA)
  • Birds (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Endocrinology (AREA)
  • Transplantation (AREA)
  • Neurosurgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biochemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Infusion, Injection, And Reservoir Apparatuses (AREA)
  • Materials For Medical Uses (AREA)

Abstract

patente de invenção: <b>"sistema de liberação controlada de líquido de alta viscosidade"<d>. composição para liberação controlada de substâncias é provida e que inclui (i) meterial veículo líquido aquo-insolúvel, não-polimérico (hvlcm) de viscosidade de menos 5.000 cp a 37°c que não cristaliza puro sob condições fisiológicas e ambientais e (ii) uma substância a ser liberada.
BRPI9609033A 1995-06-07 1996-06-07 composição e emulsão para a liberação controlada de uma substância. BRPI9609033B8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US47845095A 1995-06-07 1995-06-07
US08/474,337 US5747058A (en) 1995-06-07 1995-06-07 High viscosity liquid controlled delivery system
PCT/US1996/010055 WO1996039995A1 (en) 1995-06-07 1996-06-07 High viscosity liquid controlled delivery system

Publications (3)

Publication Number Publication Date
BR9609033A BR9609033A (pt) 1999-12-14
BR9609033B1 BR9609033B1 (pt) 2009-08-11
BRPI9609033B8 true BRPI9609033B8 (pt) 2017-04-04

Family

ID=27044421

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI9609033A BRPI9609033B8 (pt) 1995-06-07 1996-06-07 composição e emulsão para a liberação controlada de uma substância.

Country Status (13)

Country Link
EP (2) EP1525858A1 (pt)
JP (3) JP4330175B2 (pt)
CN (1) CN1225230C (pt)
AT (1) ATE287673T1 (pt)
AU (1) AU698281B2 (pt)
BR (1) BRPI9609033B8 (pt)
CA (1) CA2222567C (pt)
DE (1) DE69634277T2 (pt)
DK (1) DK1006935T3 (pt)
ES (1) ES2238693T3 (pt)
HK (1) HK1015255A1 (pt)
PT (1) PT1006935E (pt)
WO (1) WO1996039995A1 (pt)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5968542A (en) * 1995-06-07 1999-10-19 Southern Biosystems, Inc. High viscosity liquid controlled delivery system as a device
US7833543B2 (en) 1995-06-07 2010-11-16 Durect Corporation High viscosity liquid controlled delivery system and medical or surgical device
CA2222567C (en) * 1995-06-07 2002-01-29 Southern Biosystems, Inc. High viscosity liquid controlled biologically active delivery system
US6413536B1 (en) 1995-06-07 2002-07-02 Southern Biosystems, Inc. High viscosity liquid controlled delivery system and medical or surgical device
US6051558A (en) * 1997-05-28 2000-04-18 Southern Biosystems, Inc. Compositions suitable for controlled release of the hormone GnRH and its analogs
US7303756B1 (en) * 1997-06-05 2007-12-04 Bertex Pharma Gmbh Multiphase system
DE69825128T3 (de) † 1997-12-02 2010-05-06 Pfizer Products Inc., Groton Verwendung von azithromycin zur topischen behandlung von augeninfektionen
US6245345B1 (en) * 1998-07-07 2001-06-12 Atrix Laboratories, Inc. Filamentous porous films and methods for producing the same
US6239113B1 (en) 1999-03-31 2001-05-29 Insite Vision, Incorporated Topical treatment or prevention of ocular infections
US7056893B2 (en) 1999-03-31 2006-06-06 Insite Vision, Inc. Topical treatment for prevention of ocular infections
JP4601100B2 (ja) * 1999-11-08 2010-12-22 三生医薬株式会社 マスティックの油液を内包した軟カプセル
ES2554106T3 (es) 2001-06-21 2015-12-16 Genentech, Inc. Formulación de liberación sostenida
US20040001889A1 (en) 2002-06-25 2004-01-01 Guohua Chen Short duration depot formulations
ATE482695T1 (de) 2002-12-13 2010-10-15 Durect Corp Orale darreichungsform mit flüssigen hochviskosen trägersystemen
WO2004056338A2 (en) * 2002-12-19 2004-07-08 Alza Corporation Stable, non-aqueous, single-phase gels and formulations thereof for delivery from an implantable device
EP2462957B1 (en) * 2003-09-23 2019-04-24 Abyrx, Inc. Absorbable implants and methods for their use in hemostasis and in the treatment of osseous defects
JP2007506505A (ja) 2003-09-23 2007-03-22 オーソ・セラピューティクス・リミテッド・ライアビリティ・カンパニー 生体吸収性のパテ様止血性インプラント
US8603528B2 (en) 2004-09-16 2013-12-10 Abyrx, Inc. Compositions and method for the reduction of post-operative pain
LT2767292T (lt) 2004-09-17 2016-12-12 Durect Corporation Palaikomosios vietinės anestezijos mišinys su saib
DE102005002703C5 (de) 2005-01-19 2013-07-04 Heraeus Kulzer Gmbh Antibiotische Beschichtung von Implantaten sowie Verfahren zur antibiotischen Beschichtung
US20070027105A1 (en) 2005-07-26 2007-02-01 Alza Corporation Peroxide removal from drug delivery vehicle
US8852638B2 (en) 2005-09-30 2014-10-07 Durect Corporation Sustained release small molecule drug formulation
US9072673B2 (en) 2006-05-15 2015-07-07 Zicare, Llc Method for measurably improving oral health
US8871183B2 (en) 2006-05-15 2014-10-28 Zicare, Llc Composition for promoting and maintaining oral health
DK2117521T3 (da) 2006-11-03 2012-09-03 Durect Corp Transdermale indgivelsessystemer omfattende bupivacain
CN101801415B (zh) 2007-05-25 2015-09-23 Rb医药品有限公司 利培酮化合物的持续递送制剂
EP2011452B1 (fr) * 2007-07-06 2014-04-30 S.B.I.R. Sprl Préparation injectable pour la réalisation d'un implant musculaire
AU2008335809A1 (en) * 2007-12-06 2009-06-18 Durect Corporation Methods useful for the treatment of pain, arthritic conditions, or inflammation associated with a chronic condition
WO2009100216A1 (en) * 2008-02-08 2009-08-13 Qps Llc Composition for sustained release delivery of proteins or peptides
CA2714514C (en) * 2008-02-08 2016-08-16 Qps Llc Non-polymeric compositions for controlled drug delivery
US20100260844A1 (en) 2008-11-03 2010-10-14 Scicinski Jan J Oral pharmaceutical dosage forms
GB2513060B (en) 2010-06-08 2015-01-07 Rb Pharmaceuticals Ltd Microparticle buprenorphine suspension
US9272044B2 (en) 2010-06-08 2016-03-01 Indivior Uk Limited Injectable flowable composition buprenorphine
CN103830767A (zh) * 2012-11-26 2014-06-04 韩冰 乙酸异丁酸蔗糖酯凝胶及其用途
TW201521769A (zh) 2013-03-15 2015-06-16 Durect Corp 具有流變改質劑以減少溶解變異性之組成物
ES2828752T3 (es) 2013-05-24 2021-05-27 Danmarks Tekniske Univ Dtu Formulaciones en gel para guiar la radioterapia
JP6247400B2 (ja) * 2013-12-31 2017-12-13 ペベエベ・エスア 身体再建及び身体成形における使用のための制御放出脂肪酸組成物
GB201404139D0 (en) 2014-03-10 2014-04-23 Rb Pharmaceuticals Ltd Sustained release buprenorphine solution formulations
CN107249570B (zh) 2014-11-21 2022-08-09 丹麦技术大学 用于局部药物释放的凝胶制剂
SG11201809729XA (en) 2016-05-20 2018-12-28 Univ Denmark Tech Dtu Palpable marker composition
BR112018077259A2 (pt) * 2016-06-30 2019-06-18 Durect Corporation formulações depot
EA201990127A1 (ru) * 2016-12-30 2020-08-18 Дьюрект Корпорейшн Депо-препарат
WO2018225050A1 (en) 2017-06-09 2018-12-13 Association For The Advancement Of Tissue Engineering Cell Based Technologies & Therapies (A4Tec) - Associação Sucrose acetate isobutyrate-based compositions, methods and uses thereof
BR112022013784A2 (pt) 2020-01-13 2022-10-11 Durect Corp Sistemas de distribuição de fármacos de liberação prolongada com impurezas reduzidas e métodos relacionados
KR102388506B1 (ko) * 2021-06-14 2022-04-20 (주)씨앤엘디 유착방지용 조성물
WO2023063247A1 (ja) * 2021-10-13 2023-04-20 株式会社エナジーフロント 抗ウイルス剤、抗ウイルス性を付与する方法、抗ウイルス性を有する物品、抗菌剤、抗菌性を有する物品、抗真菌剤、及び抗真菌性を有する物品

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS59210024A (ja) * 1983-05-13 1984-11-28 Taiyo Kagaku Kk トコフエロ−ル乳化物
JPS62419A (ja) * 1985-06-26 1987-01-06 Shiseido Co Ltd 脂溶性ビタミン含有水溶性剤
US4938763B1 (en) * 1988-10-03 1995-07-04 Atrix Lab Inc Biodegradable in-situ forming implants and method of producing the same
US4987893A (en) * 1988-10-12 1991-01-29 Rochal Industries, Inc. Conformable bandage and coating material
WO1993003751A1 (en) * 1991-08-26 1993-03-04 Abbott Laboratories Compositions and methods for the sublingual or buccal administration of therapeutic agents
IL103275A0 (en) * 1991-10-01 1993-02-21 Lilly Co Eli Injectable extended release formulations and methods
WO1993011754A1 (en) * 1991-12-11 1993-06-24 The Procter & Gamble Company Cetylpyridinium chloride and domiphen bromide in organic solvent
US5340572A (en) * 1993-02-08 1994-08-23 Insite Vision Incorporated Alkaline ophthalmic suspensions
US5370864A (en) * 1993-06-29 1994-12-06 The Procter & Gamble Company Breath protection microcapsules
JPH0753356A (ja) * 1993-08-16 1995-02-28 Morishita Jintan Kk 酸化され易い油性物質を内容物とするシームレスカプセルおよびその製造方法
TW282403B (pt) * 1993-08-26 1996-08-01 Takeda Pharm Industry Co Ltd
JPH09507233A (ja) * 1993-12-29 1997-07-22 マトリクス ファーマスーティカル，インコーポレイティド 細胞増殖性疾患に罹る宿主の治療方法及び治療のための組成物
CA2222567C (en) * 1995-06-07 2002-01-29 Southern Biosystems, Inc. High viscosity liquid controlled biologically active delivery system

Also Published As

Publication number Publication date
AU6273196A (en) 1996-12-30
JP2007126459A (ja) 2007-05-24
ATE287673T1 (de) 2005-02-15
JPH11507278A (ja) 1999-06-29
EP1006935B1 (en) 2005-01-26
JP2009197018A (ja) 2009-09-03
MX9709606A (es) 1998-06-30
PT1006935E (pt) 2005-06-30
EP1006935A4 (en) 2001-05-02
CA2222567A1 (en) 1996-12-19
HK1015255A1 (en) 1999-10-15
DK1006935T3 (da) 2005-06-06
BR9609033A (pt) 1999-12-14
BR9609033B1 (pt) 2009-08-11
DE69634277T2 (de) 2006-01-05
CN1192131A (zh) 1998-09-02
ES2238693T3 (es) 2005-09-01
JP4330175B2 (ja) 2009-09-16
AU698281B2 (en) 1998-10-29
WO1996039995A1 (en) 1996-12-19
EP1525858A1 (en) 2005-04-27
EP1006935A1 (en) 2000-06-14
CN1225230C (zh) 2005-11-02
DE69634277D1 (de) 2005-03-03
CA2222567C (en) 2002-01-29

Similar Documents

Publication Publication Date Title
BRPI9609033B8 (pt) composição e emulsão para a liberação controlada de uma substância.
WO1999013913A3 (en) High viscosity liquid controlled delivery system as a device
BR9809189A (pt) Compostos adequados para liberação controlada do hormÈnio gnrh e seus análogos
MX170784B (es) Composicion cosmetica que contiene diorganopolisiloxanos con funcion benzotriazol para la proteccion de la piel y el cabello
ATE200184T1 (de) Arzneimittelhaltiges tierfutter
NZ311208A (en) Composition comprising an active agent dissolved in a glass-forming carrier comprising a glass-forming substance containing a plasticizer, composition is liquid or jelly-like below 50 degrees
MX9100423A (es) Composiciones liquidas y estabilizadas para el tratamiento de la piel y fibras
DK647789D0 (da) Kosmetisk eller farmaceutisk komposition indeholdende mikrosfaerer af polymere eller af fedtstofferforsynet med mindst et aktivt produkt
BR0105456A (pt) Dispositivo de condicionamento comportando uma unidade
PT774962E (pt) Utilizacao de dha como uma composicao farmaceutica
FI952461A0 (fi) Antolaite, jossa on kapseloituja täyteaineita
DK626484D0 (da) Systemer til afgivelse af virksomme stoffer
KR890000085A (ko) 필수지방산 합성물(Essential Fatty Acid Compositions)
ATE154235T1 (de) Kosmetische oder pharmazeutische zusammensetzungen zur topischen anwendung die deacylierten glycerophospholipide enthalten
ES2141736T3 (es) Gel, especialmente para uso terapeutico ocular.
DK1178854T3 (da) Indretning til transkutan indgivelse af molekyler indeholdt i et relativt viskost bærerstof, såsom en gel eller lignende
CA2140032A1 (en) Cross-linked amylose material for enzymatically controlled drug release
KR850000968A (ko) 피부 보호 조성물의 제조 방법
MX9302986A (es) Medicamento que contiene metrifonato y procedimiento para su preparacion
DE59801586D1 (de) Zur topischen applikation bestimmte diclofenac-lösung
KR900017599A (ko) 종양 치료용 약학 조성물
KR890001567A (ko) 디플루니살 및 트로메타민-함유 조성물
AU5766790A (en) Liquid polymer composition, and method of use
KR890001549A (ko) 위염 치료제
KR970073564A (ko) N-메칠-2-피로리돈을 주성분 또는 보조성분으로 한 메니큐어 리무버

Legal Events

Date Code Title Description
FD5 Application fees: dismissal - article 86 of industrial property law
HIX Notification cancelled
EG Technical examination (opinion): publication of technical examination (opinion)
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: INDEFIRO O PEDIDO DE PATENTE COM BASE NO ARTIGO 24 DA LPI NO 9.279 DE 14/05/1996.

B25A Requested transfer of rights approved

Owner name: DURECT CORPORATION (US)

Free format text: TRANSFERIDO POR FUSAO DE: SOUTHERN BIOSYSTEMS, INC.

B12B Appeal against refusal [chapter 12.2 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B09Y Publication of grant cancelled [chapter 9.1.2 patent gazette]

Free format text: REFERENTE A RPI 1982 DE 30/12/2008.

B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 20/10/2009, OBSERVADAS AS CONDICOES LEGAIS.

B22O Other matters related to patents and certificates of addition of invention: legal action concerning patent

Free format text: INPI-524000.061598/2013 ORIGEM: JUIZO DA 013A VARA FEDERAL DO RIO DE JANEIRO PROCESSO NO 0132260-18.2013.4.02.5101 ACAO DE NULIDADE DAS PATENTES SUBMETIDAS AO MAILBOX (ART. 229, PARAGRAFO UNICO DA LPI); ALTERNATIVAMENTE, A DECRETACAO DA NULIDADE PARCIAL PARA CORRECAO DO PRAZO DE VIGENCIA; SUBSIDIARIAMENTE, CASO SE ENTENDA NAO SER O CASO DE NULIDADE, A CORRECAO DO ATO ADMINISTRATIVO PARA ADEQUACAO DA VIGENCIA DAS PATENTES. AUTOR: INSTITUTO NACIONAL DA PROPRIEDADE INDUSTRIAL - INPI REU: D. WESTERN THERAPEUTICS INSTITUTE, KOWA COMPANY, LTD., DURECT CORPORATION, ELANCO ANIMAL HEALTH IRELAND LIMITED, EUROVITA A/S, EVONIK GOLDSCHMIDT GMBH

B19A Notification of judicial decision: notification of judicial decision
B16C Correction of notification of the grant [chapter 16.3 patent gazette]
B21A Patent or certificate of addition expired [chapter 21.1 patent gazette]

Free format text: PATENTE EXTINTA EM 07/06/2016